Five Prime Therapeutics Stock News

Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre

A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filing

Five Prime Therapeutics (NASDAQ: FPRX) shares are trading higher on Monday after Wedbush upgraded the company's stock from Neutral to Outperform and raised its price target from $5 to $9.Five Prime Th

Five Prime Therapeutics (NASDAQ:FPRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The firm currently

Q1 2020 Five Prime Therapeutics Inc Earnings Call

Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) just released its first-quarter report and things are looking bullish...

Q1 2020 Five Prime Therapeutics Inc Earnings Call

Wall Street securities analysts on Friday revised their ratings and price targets on several U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings. HIGHLIGHTS